Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Royalty Pharma delivered a solid third quarter, showcasing an 11% growth in both their portfolio receipts and royalty receipts.</li><li>This growth is largely driven by their diversified portfolio, which remains a key strength of the company.</li><li>Their stable returns on invested capital at 15.7% and returns on invested equity at 22.9% demonstrate efficient capital management.</li></ul>

Royalty Pharma delivered a solid third quarter, showcasing an 11% growth in both their portfolio receipts and royalty receipts.This growth is largely driven by their diversified portfolio, which remains a key strength of the company.Their stable returns on invested capital at 15.7% and returns on invested equity at 22.9% demonstrate efficient capital management.

Royalty Pharma: Can Imdelltra’s $700 Million Launch Ignite a Multi-Billion Dollar Cancer Breakthrough?

<ul><li>Royalty Pharma's recent earnings for the second quarter of 2025 showcased significant progress, underscoring both strengths and areas of potential concern.</li><li>Positively, Royalty Pharma achieved a 20% increase in Portfolio Receipts, reaching $727 million, surpassing prior guidance.</li><li>The company also reported an 11% rise in Royalty Receipts to $672 million, attributed to the robust performance of its diversified portfolio.</li></ul>

Royalty Pharma's recent earnings for the second quarter of 2025 showcased significant progress, underscoring both strengths and areas of potential concern.Positively, Royalty Pharma achieved a 20% increase in Portfolio Receipts, reaching $727 million, surpassing prior guidance.The company also reported an 11% rise in Royalty Receipts to $672 million, attributed to the robust performance of its diversified portfolio.

Royalty Pharma Eyes China’s Biotech Boom—Can Early Bets Deliver Solid Future Payouts?

<ul><li>Royalty Pharma PLC's recent earnings results for the first quarter of 2025 outline a period of significant financial performance and strategic initiatives.</li><li>The company reported a 12% increase in royalty receipts, demonstrating solid cash flow stemming from its diversified portfolio.</li><li>Total portfolio receipts grew by 17%, boosted by variable milestones and contractual payments, indicating a strong top-line performance.</li></ul>

Royalty Pharma PLC's recent earnings results for the first quarter of 2025 outline a period of significant financial performance and strategic initiatives.The company reported a 12% increase in royalty receipts, demonstrating solid cash flow stemming from its diversified portfolio.Total portfolio receipts grew by 17%, boosted by variable milestones and contractual payments, indicating a strong top-line performance.

Royalty Pharma Flexes Financial Muscle: A $723 Million In Share Repurchases & Bold 2025 Outlook!

<ul><li>Royalty Pharma has reported robust financial results for the fourth quarter and full year 2024, underscoring its position as a leading funder of innovation within the life sciences sector.</li><li>With a significant emphasis on strategic capital deployment, Royalty Pharma achieved portfolio receipts of $2.8 billion, marking a commendable 13% growth and surpassing initial guidance expectations of 5% to 9%.</li><li>This financial performance reflects the company's adept management and its capacity to expand its portfolio effectively.</li></ul>

Royalty Pharma has reported robust financial results for the fourth quarter and full year 2024, underscoring its position as a leading funder of innovation within the life sciences sector.With a significant emphasis on strategic capital deployment, Royalty Pharma achieved portfolio receipts of $2.8 billion, marking a commendable 13% growth and surpassing initial guidance expectations of 5% to 9%.This financial performance reflects the company's adept management and its capacity to expand its portfolio effectively.

Royalty Pharma: These Are The Major Shifts That Could Redefine Biopharma Royalties!

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We downgraded our near-term outlook on SPX and QQQ to neutral last week (11/19/25), after being bullish since 4/22/25, while we maintained our intermediate-term bullish outlook (as of 5/14/25).</li>
<li>Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are back to being near-term bullish as long as these supports continue to hold</li>
<li>The latest pullback offers an attractive entry point into all the speculative growth areas that we were pounding the table on since May, WITH A STOP AT LAST WEEKS LOWS</li>
</ul>


We downgraded our near-term outlook on SPX and QQQ to neutral last week (11/19/25), after being bullish since 4/22/25, while we maintained our intermediate-term bullish outlook (as of 5/14/25).
Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are back to being near-term bullish as long as these supports continue to hold
The latest pullback offers an attractive entry point into all the speculative growth areas that we were pounding the table on since May, WITH A STOP AT LAST WEEKS LOWS


Back to Near-Term Bullish on SPX and Nasdaq 100; Supports Held at SPX 6480-6520 and QQQ $580-583

United States

Royalty Pharma plc acquires biopharmaceutical royalties. The Company funds innovation directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Royalty Pharma (RPRX US)

Royalty Pharma: Can Imdelltra’s $700 Million Launch Ignite a Multi-Billion Dollar Cancer Breakthrough?

Royalty Pharma delivered a solid third quarter, showcasing an 11% growth in both their portfolio receipts and royalty receipts. This growth is...

Baptista Research

Royalty Pharma Eyes China’s Biotech Boom—Can Early Bets Deliver Solid Future Payouts?

Royalty Pharma's recent earnings for the second quarter of 2025 showcased significant progress, underscoring both strengths and areas of potential...

Baptista Research

Royalty Pharma: These Are The Major Shifts That Could Redefine Biopharma Royalties!

Royalty Pharma has reported robust financial results for the fourth quarter and full year 2024, underscoring its position as a leading funder of...

Baptista Research

Back to Near-Term Bullish on SPX and Nasdaq 100; Supports Held at SPX 6480-6520 and QQQ $580-583

Back to Near-Term Bullish on $SPX and Nasdaq 100 $NDX; Crucial Supports Held at 6480-6520 on SPX and $580-$583 on $QQQ, we are near-term bullish as...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Royalty Pharma: Can Imdelltra’s $700 Million Launch Ignite a Multi-Billion Dollar Cancer Breakthrough?

Royalty Pharma delivered a solid third quarter, showcasing an 11% growth in both their portfolio receipts and royalty receipts. This growth is...

Baptista Research

Royalty Pharma Eyes China’s Biotech Boom—Can Early Bets Deliver Solid Future Payouts?

Royalty Pharma's recent earnings for the second quarter of 2025 showcased significant progress, underscoring both strengths and areas of potential...

Baptista Research

Royalty Pharma Flexes Financial Muscle: A $723 Million In Share Repurchases & Bold 2025 Outlook!

Royalty Pharma PLC's recent earnings results for the first quarter of 2025 outline a period of significant financial performance and strategic...

Baptista Research

Royalty Pharma: These Are The Major Shifts That Could Redefine Biopharma Royalties!

Royalty Pharma has reported robust financial results for the fourth quarter and full year 2024, underscoring its position as a leading funder of...

Baptista Research

Back to Near-Term Bullish on SPX and Nasdaq 100; Supports Held at SPX 6480-6520 and QQQ $580-583

Back to Near-Term Bullish on $SPX and Nasdaq 100 $NDX; Crucial Supports Held at 6480-6520 on SPX and $580-$583 on $QQQ, we are near-term bullish as...

Vermilion Research